<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238482</url>
  </required_header>
  <id_info>
    <org_study_id>3106012</org_study_id>
    <nct_id>NCT03238482</nct_id>
  </id_info>
  <brief_title>Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)</brief_title>
  <official_title>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler 50/250 µg/Dose Products and Seretide Diskus 50/250 µg/Dose in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare absorption of salmeterol and fluticasone from
      Salmeterol/fluticasone Easyhaler test products to the commercially available product Seretide
      Diskus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">December 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of salmeterol</measure>
    <time_frame>between 0-34 hours after dosing</time_frame>
    <description>Cmax of salmeterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of fluticasone propionate</measure>
    <time_frame>between 0-34 hours after dosing</time_frame>
    <description>Cmax of fluticasone propionate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of salmeterol</measure>
    <time_frame>0-34 hours after dosing</time_frame>
    <description>AUC from time zero to the last sample with the quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of fluticasone propionate</measure>
    <time_frame>0-34 hours after dosing</time_frame>
    <description>AUC from time zero to the last sample with the quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Truncated area under the plasma concentration versus time curve (AUC) of salmeterol</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>AUC from time zero to 30 min after study treatment administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of salmeterol</measure>
    <time_frame>0-34 hours after dosing and extrapolation</time_frame>
    <description>AUC from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of fluticasone propionate</measure>
    <time_frame>0-34 hours after dosing and extrapolation</time_frame>
    <description>AUC from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to reach the maximum concentration (tmax) of salmeterol</measure>
    <time_frame>0-34 hours after dosing</time_frame>
    <description>tmax of salmeterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to reach the maximum concentration (tmax) of fluticasone propionate</measure>
    <time_frame>0-34 hours after dosing</time_frame>
    <description>tmax of fluticasone propionate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The terminal elimination half-life (t1/2) of salmeterol</measure>
    <time_frame>0-34 hours after dosing</time_frame>
    <description>t1/2 of salmeterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The terminal elimination half-life (t1/2) of fluticasone propionate</measure>
    <time_frame>0-34 hours after dosing</time_frame>
    <description>t1/2 of fluticasone propionate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Seretide Diskus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>salmeterol-fluticasone 2 inhalations as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone Easyhaler, E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salmeterol-fluticasone 2 inhalations as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone Easyhaler, F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salmeterol-fluticasone 2 inhalations as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone Easyhaler, G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salmeterol-fluticasone 2 inhalations as a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol-fluticasone</intervention_name>
    <description>Seretide Diskus 50/250 µg/dose</description>
    <arm_group_label>Seretide Diskus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol-fluticasone</intervention_name>
    <description>Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E</description>
    <arm_group_label>Salmeterol/fluticasone Easyhaler, E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol-fluticasone</intervention_name>
    <description>Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F</description>
    <arm_group_label>Salmeterol/fluticasone Easyhaler, F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol-fluticasone</intervention_name>
    <description>Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G</description>
    <arm_group_label>Salmeterol/fluticasone Easyhaler, G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          1. Written informed consent (IC) obtained.

          2. Males and females, 18-60 (inclusive) years of age.

          3. Normal weight defined as body mass index (BMI) 19-30 kg/m2 (BMI = weight/height2).

          4. Weight at least 50 kg.

        Main exclusion Criteria:

          1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             GI, pulmonary, metabolic, endocrine, neurological or psychiatric disease.

          2. Any condition requiring regular concomitant treatment.

          3. Any clinically significant abnormal laboratory value or physical finding that in the
             opinion of the investigator may interfere with the interpretation of study results or
             constitute a health risk for the subject if he/she takes part in the study.

          4. Known hypersensitivity to the active substance(s) or the lactose.

          5. Pregnant or lactating females and females of childbearing potential not using proper
             contraception.

          6. Blood donation or loss of significant amount of blood within 90 days prior to first
             study treatment administration.

          7. Administration of another investigational medicinal product within 90 days prior to
             first study treatment administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla Sairanen</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit, Orion Pharma</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

